VivoSim Labs, Inc. (NASDAQ:VIVS) Short Interest Update
by Scott Moore · The Cerbat GemVivoSim Labs, Inc. (NASDAQ:VIVS – Get Free Report) saw a significant growth in short interest in July. As of July 31st, there was short interest totaling 570,467 shares, a growth of 1,070.7% from the July 15th total of 48,730 shares. Based on an average trading volume of 8,475,803 shares, the days-to-cover ratio is presently 0.1 days. Approximately 16.7% of the company’s shares are short sold.
VivoSim Labs Stock Down 3.2%
Shares of VivoSim Labs stock traded down $0.01 on Tuesday, hitting $0.35. The company had a trading volume of 3,220,143 shares, compared to its average volume of 16,634,510. The stock has a 50-day moving average of $0.81 and a 200-day moving average of $1.39. VivoSim Labs has a twelve month low of $0.31 and a twelve month high of $5.30.
VivoSim Labs (NASDAQ:VIVS – Get Free Report) last issued its quarterly earnings data on Tuesday, July 14th. The company reported ($2.21) EPS for the quarter. The company had revenue of $0.04 million for the quarter. VivoSim Labs had a negative return on equity of 277.62% and a negative net margin of 10,567.17%.
Institutional Trading of VivoSim Labs
An institutional investor recently bought a new position in VivoSim Labs stock. Two Sigma Investments LP acquired a new position in shares of VivoSim Labs, Inc. (NASDAQ:VIVS – Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned 0.89% of VivoSim Labs at the end of the most recent reporting period. 8.23% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Separately, Weiss Ratings cut VivoSim Labs from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 22nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.
VivoSim Labs Company Profile
VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.
The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.